Treatment of ankylosing spondylitis: focus on etanercept.
Ankylosing spondylitis is a chronic inflammatory condition which preferentially affects the axial skeleton, often beginning in the sacroiliac joints. The etiology of the pathologic lesions of this condition including enthesitis, erosive articular changes, osteitis, and fibrous ankylosis, as well as changes which occur in the eye, gastrointestinal tract, cardiovascular system, and lungs is unknown; however, there is a strong association with HLA-B27, which indicates altered immunity. One of the major mediators of the immune response is TNF-alpha, which functions as a pleiotrophic soluble messenger primarily from macrophages. TNF-alpha is principally involved with activation of both normal and transformed cells, including endothelium, synoviocytes, osteoclasts, chondrocytes, and fibroblasts. The cornerstone of medical management of ankylosing spondylitis includes intensive physical therapy and nonsteroidal anti-inflammatories for symptomatic relief. However, it is becoming increasingly recognized that TNF-alpha blockade has an important role in the reduction of spine and joint inflammation. This review discusses the data that supports use of etanercept in the treatment of ankylosing spondylitis.
Frech
Tracy
T
University of Utah, Division of Rheumatology, UT, USA.
Ann Rheum Dis. 2006 Sep;65(9):1184-7
16414970
Arthritis Rheum. 2001 Sep;44(9):2112-7
11592375
Best Pract Res Clin Rheumatol. 2006 Jun;20(3):401-17
16777573
Arthritis Rheum. 2003 Nov;48(11):3230-6
14613288
Ann Rheum Dis. 2004 Sep;63(9):1041-5
15066864
Arthritis Rheum. 2003 Nov;48(11):3013-22
14613261
J Intensive Care Med. 2004 Nov-Dec;19(6):320-34
15523118
Ann Rheum Dis. 2006 Apr;65(4):423-32
16126792
J Rheumatol. 1994 Oct;21(10):1883-7
7837155
Arthritis Rheum. 1999 Nov;42(11):2325-9
10555027
J Rheumatol. 1998 Apr;25(4):714-7
9558174
Ann Rheum Dis. 2003 May;62(5):455-9
12695160
Best Pract Res Clin Rheumatol. 2006 Aug;20(4):757-90
16979537
Curr Opin Rheumatol. 2001 Jul;13(4):265-72
11555726
J Neurosurg. 1993 Jun;78(6):871-8
8487068
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004524
17054209
J Rheumatol. 1995 Dec;22(12):2266-72
8835560
Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S158-61
12463469
Arthritis Rheum. 1994 Jul;37(7):1039-45
8024613
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004800
15846731
J Med Microbiol. 2000 Apr;49(4):305-311
10755623
Arthritis Rheum. 2001 Dec;44(12):2862-9
11762947
Rheum Dis Clin North Am. 1998 Nov;24(4):785-813, ix-x
9891711
Mol Med Today. 2000 Jun;6(6):224-30
10840380
J Rheumatol. 2005 Oct;32(10):1899-906
16206344
Immunol Lett. 2007 Jan 15;108(1):27-33
17129613
Ophthalmology. 2006 Dec;113(12):2317-23
16996615
Arthritis Rheum. 1995 Apr;38(4):499-505
7718003
Arthritis Rheum. 1984 Apr;27(4):361-8
6231933
Cytokine. 2004 Nov 21-Dec 7;28(4-5):179-81
15588693
J Rheumatol. 2006 Nov;33(11):2167-72
16981296
Arthritis Rheum. 2006 Feb;54(2):569-78
16447233
Rheumatology (Oxford). 2005 Mar;44(3):342-8
15561737
Br J Rheumatol. 1994 Oct;33(10):927-31
7921752
Br J Rheumatol. 1997 Jul;36(7):766-71
9255111
Arthritis Rheum. 2005 Aug;52(8):2447-51
16052578
Arthritis Rheum. 1995 May;38(5):618-27
7748217
Ann Rheum Dis. 2005 Nov;64(11):1557-62
15843448
Ann Rheum Dis. 2004 Dec;63(12):1594-600
15345498
Curr Opin Pulm Med. 2006 Sep;12(5):342-5
16926649
Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii9-23
12381507
Curr Opin Rheumatol. 1998 Jul;10(4):314-8
9725092
J Rheumatol. 2006 Dec;33(12):2440-6
17014005
Drugs. 2004;64(24):2793-811
15563249
Ann Rheum Dis. 2006 Apr;65(4):442-52
16126791
Rheumatology (Oxford). 2007 Feb;46(2):327-34
16880188
N Engl J Med. 2002 May 2;346(18):1349-56
11986408
Med J Aust. 2005 Aug 15;183(4):205-8
16097922
J Rheumatol. 1997 Mar;24(3):507-10
9058657